Protalix BioTherapeutics, Inc.
- Jurisdiction
United States - LEI
549300SDVB3GP4XDFM60 - ISIN
US74365A3095 (PLX )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
5
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
5
/ 7
Profile
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. Read full profile
Stock price
Fundamentals
- Net revenue
€53.15M - Gross margin
57.5% - EBIT
€7.06M - EBIT margin
13.3% - Net income
€5.38M - Net margin
10.1%
Statement period: - (published )
Dividends
No dividend payouts
Earnings Calls
Latest earnings call: August 14, 2025
Investor transactions
| Name | Shares | Value | Last change | Change type |
|---|---|---|---|---|
| Peter Brown |
|
|
|
Buy |